Early anatomical outcomes of faricimab vs aflibercept 2 mg in treatment-naïve neovascular age-related macular degeneration and polypoidal choroidal vasculopathy: A head-to-head comparative study in Taiwan.

J Chin Med Assoc · 2026 · PMC12815515 · PMID 41276957

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The aflibercept group showed a trend toward improved BCVA, however, the improvement was not significant at any time point (0.78 ± 0.41 to 0.72 ± 0.60 [ p = 0.348] at 4 months).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.